MSD Animal Health Announces Call for Nominations for 2024 High-Quality Pork Pignnovation Award

Award to Recognize Three Cutting-Edge Organizations, Startups or Individuals who Promote a Positive Change in the Swine Industry

Award Accepting Nominations Through June 30, 2024

RAHWAY, N.J., April 5, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it is now accepting nominations for the High-Quality Pork Pignnovation Award. The High-Quality Pork program was created to support the swine industry with the latest information to advance the state of pig farming. This year’s award will recognize three organizations, startups or individuals who are working to advance swine innovation and technology with demonstrated proof of concept in reproduction, growth, health, welfare or sustainability.

“MSD Animal Health is excited to announce the High-Quality Pork Pignnovation Award,” said Tiago Arantes, associate vice president, Livestock Global Marketing, MSD Animal Health. “This award, which will support and elevate the lastest innovations in swine, will help us continue to advance animal health around the globe.”

A total of $150,000 (US) will be divided awarded to three winners: Champion ($75,000), Runner-Up, ($50,000) and Third Place ($25,000). Winners will be announced in September 2024.

For more information about the award and to apply visit: Applications will close on June 30, 2024.

Application and Selection Criteria

Applications are invited from organizations and individuals with solutions and ideas poised to drive innovation and change in the swine industry combining technology. Applications will be judged on the quality and clarity of their project proposal, realistic aspirations of the proposed project, the project’s potential value in terms of relevance and its societal or welfare impact and originality. The winners will be selected based on merit after a competitive review process. This final selection of the winners will be made by a panel composed of members from MSD Animal Health as well as independent industry judges.

Each application should include a three-step business plan that contains an executive summary, clearly defined problem statement and market analysis. It should offer the methods of research, expected outcomes and budgetary requirements. The project must be an applied project in swine innovation and technology with demonstrated proof of concept in reproduction, growth, health, welfare or sustainability.

About MSD Animal Health

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn and X (formerly Twitter).

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (